Dr. Salam’s Research

Genetic Variations & Clinical Efficacy of Nalbuphine in Postoperative Pain

Due to limited opioid availability, there is widespread perioperative use of nalbuphine in LMICs, however, its pharmacogenomic profile remains poorly understood, particularly in genetically distinct populations. Addressing this gap in knowledge is essential for optimizing postoperative pain management where nalbuphine is a frontline analgesic. The primary aim of this project is to investigate the association between genetic variations and the clinical analgesic efficacy of nalbuphine. By identifying variants associated with analgesic response, side-effect profiles, and recovery outcomes, Dr. Salam seeks to identify a personalized approach to postoperative pain management. Her research aims to provide context-specific pharmacogenomic evidence for opioid use in LMICs. The findings may enable optimized dosing strategies, reduced adverse effects, and tailored opioid-sparing protocols. Capacity building will take place as additional regional healthcare professionals will be trained in opioid pharmacogenomics and genetic testing relevant to anesthesia and pain management.